CN120225196A - 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物 - Google Patents

含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物 Download PDF

Info

Publication number
CN120225196A
CN120225196A CN202380079383.3A CN202380079383A CN120225196A CN 120225196 A CN120225196 A CN 120225196A CN 202380079383 A CN202380079383 A CN 202380079383A CN 120225196 A CN120225196 A CN 120225196A
Authority
CN
China
Prior art keywords
liposome
dna damage
inhibitor
topotecan
damage repair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380079383.3A
Other languages
English (en)
Chinese (zh)
Inventor
下山晋
冈田健
森干永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN120225196A publication Critical patent/CN120225196A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380079383.3A 2022-11-21 2023-11-21 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物 Pending CN120225196A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022185972 2022-11-21
JP2022-185972 2022-11-21
PCT/JP2023/041699 WO2024111564A1 (ja) 2022-11-21 2023-11-21 トポテカン又はその塩を内包するリポソーム組成物およびｄｎａ損傷修復阻害剤を含む組合せ医薬

Publications (1)

Publication Number Publication Date
CN120225196A true CN120225196A (zh) 2025-06-27

Family

ID=91195598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380079383.3A Pending CN120225196A (zh) 2022-11-21 2023-11-21 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物

Country Status (6)

Country Link
US (1) US20250268827A1 (https=)
EP (1) EP4623915A4 (https=)
JP (1) JPWO2024111564A1 (https=)
CN (1) CN120225196A (https=)
TW (1) TW202434243A (https=)
WO (1) WO2024111564A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
JP7042739B2 (ja) * 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
EP4647126A3 (en) * 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
EP3423048A4 (en) * 2016-02-29 2019-10-23 Synta Pharmaceuticals Corp. COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER
RU2734900C1 (ru) 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
TWI837189B (zh) 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
JPWO2022250013A1 (https=) * 2021-05-24 2022-12-01

Also Published As

Publication number Publication date
TW202434243A (zh) 2024-09-01
EP4623915A4 (en) 2026-04-01
WO2024111564A1 (ja) 2024-05-30
JPWO2024111564A1 (https=) 2024-05-30
EP4623915A1 (en) 2025-10-01
US20250268827A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
EP3372232B1 (en) Tumor therapeutic agent comprising gemcitabine liposome composition and kit
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
JPWO2009096487A1 (ja) オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
ES2984148T3 (es) Medicamento de combinación que contiene una composición liposómica que encapsula un fármaco y un inhibidor de punto de control inmunitario
CN120225196A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
CN117440810A (zh) 抗肿瘤剂
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
HK40122907A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
EP3395370B1 (en) Liposome and liposome composition
AU2021249949B2 (en) Antitumor agent
HK40102143A (zh) 抗肿瘤剂
HK40045737A (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
WO2022250015A1 (ja) 処置剤
TW202203943A (zh) 抗腫瘤劑
HK40041777B (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
HK40041777A (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
JPWO2009125858A1 (ja) ２−インドリノン誘導体を含有する脂質分散体製剤
HK40014043A (en) Liposomal formulation for use in the treatment of cancer
HK40014043B (en) Liposomal formulation for use in the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40122907

Country of ref document: HK